Dupixent is manufactured using recombinant DNA technology [1]. This process involves genetically engineering Chinese hamster ovary (CHO) cells to produce dupilumab, the active ingredient in Dupixent [1]. These engineered cells are then cultured in bioreactors under controlled conditions to allow them to produce the antibody [1]. Following the cell culture, the dupilumab is harvested and purified through a series of complex filtration and chromatography steps to ensure its safety and efficacy [1]. The final product is a sterile, liquid solution [1].
What is Dupixent used for?
Dupixent is used to treat moderate-to-severe atopic dermatitis in adult and pediatric patients 6 months of age and older whose disease is not adequately controlled with topical therapies or when those therapies are not advisable [2]. It is also indicated for the treatment of adults and children 12 years of age and older with inadequately controlled moderate-to-severe asthma with an eosinophilic phenotype or oral corticosteroid-dependent asthma [2]. Additionally, Dupixent is approved for adults with chronic rhinosinusitis with nasal polyposis (CRSwNP) [2].
How does Dupixent work?
Dupixent targets the IL-4 receptor alpha (IL-4Rα) subunit, which is shared by the interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling pathways [2]. These cytokines play a central role in Type 2 inflammation, a key driver of atopic dermatitis, asthma, and CRSwNP [2]. By blocking IL-4Rα, Dupixent inhibits the signaling of both IL-4 and IL-13, thereby reducing inflammation associated with these conditions [2].
What are the potential side effects of Dupixent?
Common side effects of Dupixent include injection site reactions, conjunctivitis, oral herpes, and increased eosinophil count [2]. Other potential side effects can vary depending on the condition being treated. For instance, in asthma patients, paradoxical bronchospasm and anaphylaxis have been reported [2].
How is Dupixent administered?
Dupixent is administered as a subcutaneous injection [2]. The typical starting dose for atopic dermatitis in adults and children 12 years and older is 600 mg (two 300 mg injections) initially, followed by 300 mg every two weeks thereafter [2]. Dosing for other age groups and indications may differ [2].
What is the patent status for Dupixent?
Information regarding the patent exclusivity for Dupixent and its potential for generic competition can be found on DrugPatentWatch.com [3].
Who manufactures Dupixent?
Dupixent is manufactured by Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme [2].
How does Dupixent compare to other biologic treatments?
Dupixent's mechanism of action, targeting the IL-4Rα pathway, distinguishes it from other biologics that may target different cytokines or receptors involved in Type 2 inflammation [4]. For example, some treatments target IL-5 or IgE [4]. The efficacy and side effect profiles can vary between these different classes of biologic therapies, and treatment selection is often based on the specific condition, patient characteristics, and physician judgment [4].
How long does Dupixent take to start working?
Many patients experience improvement in their symptoms within two to four weeks of starting Dupixent treatment [5]. However, the full therapeutic effect may take longer to achieve [5].
Sources:
[1] https://www.regeneron.com/science/dupixent
[2] https://www.dupixent.com/
[3] https://www.drugpatentwatch.com/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016711/
[5] https://www.dupixent.com/dupixent-benefits